Atorvastatin/fluvastatin/simvastatin Reactions 1680, p62 - 2 Dec 2017 Muscle pain: case report A-56-year-old man developed muscle pain/complaints during treatment with atorvastatin, simvastatin and fluvastatin [routes, time to reactions onsets and outcomes not stated]. In March 2016, the man, with progressive angina pectoris (90% left anterior descending stenosis, one stent) presented to the clinic. He was started on treatment with atorvastatin 20 mg/day which induced muscle pain. Later on, atorvastatin treatment was switched to simvastatin 20 mg/day; however, he reported muscle complaints. His low density lipoprotein (LDL) cholesterol concentration was at 4.8 mmol/L (185 mg/dL), creatine kinase was at 3.52 mmol/L (normal range: less than 3.17) and lipoprotein (a) level was at 173 nmol/L, which prompted urgent lipid lowering drug therapy. Thus he was started on treatment with ezetimibe, which decreased LDL cholesterol to 3.6 mmol/L (138 mg/dL), without causing muscle pains. In order to achieve LDL cholesterol target value of 1.8 mmol/L (70 mg/dL) or better below 1.4 mmol/L (45 mg/dL), fluvastatin was started with a slow increase in the drug dose up to 60 mg/day; however, he developed non-severe muscle pain on fluvastatin treatment. His creatine kinase level was between 3.9 and 6.2 mmol/L, and LDL cholesterol was between 1.9 and 2.2 mmol/L (73-85 mg/dL). The man’s fluvastatin dose was decreased to 40 mg/day. As the target value for LDL cholesterol was not achieved, cholestyramine was administered and he was able to tolerate the drug at low dose. Author comment: "Statins have become an established option in lipid-lowering pharmacotherapy despite the fact that statin intolerance is fairly common. When muscle pains and/or an elevation of the creatine kinase appear, the dose must be lowered in patients with slight symptoms or stopped altogether if the symptoms are more severe." Fischer S, et al. Management of patients with statin intolerance. Atherosclerosis Supplements 30: 33-37, Nov 2017. Available from: URL: j.atherosclerosissup.2017.05.013 - Germany 803284401 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial